Table 2.

Frequency of clinical manifestations at the start of treatment with IL-1 inhibitors and after 1, 3, 6 and 12 months of therapy.

	Chest pain	Pharyngitis	Oral aphthosis	Skin rash	Pericarditis	Lymphoadenitis	Abdominal pain	Myalgia	Arthralgia	Arthritis	Conjunctivitis	Periorbital edema
Baseline	8 (40%)	8 (40%)	7 (35%)	9 (45%)	6 (30%)	6 (30%)	11 (55%)	14 (70%)	15 (75%)	6 (30%)	3 (15%)	0
Month-1	2* (10%)	0*	0*	2 (10%)	1 (5%)	2 (10%)	4 (20%)	3** (15%)	7 (35%)	1 (5%)	0	0
Month-3	0*	0*	0*	1* (5%)	0*	1 (5%)	2* (10%)	0**	4* (20%)	0	0	0
Month-6	1 (5%)	2 (10%)	0*	1 (5%)	0*	1 (5%)	1 (5%)	1** (5%)	4* (20%)	0	0	1 (5%)
Month-12	2 (10%)	3 (15%)	0*	1 (5%)	1 (5%)	2 (10%)	1 (5%)	2* (10%)	4* (20%)	0	0	1 (5%)

Statistical significance is referred to the comparison of each timepoint with the baseline assessment: *p < 0.05 **p < 0.01.